Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 18
Summary
- Conditions
- Post Essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis
- Primary Myelofibrosis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Open label, non-randomized, prospective, single-arm studyMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03627403
- Collaborators
- Karyopharm Therapeutics Inc
- Investigators
- Principal Investigator: Srinivas Tantravahi, MD University of Utah
Get Well Soon